At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 26 enrolled
Drug / intervention
Amifampridine Phosphate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Double-Blind, Placebo-controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome
In Brief
A Phase 3 clinical trial evaluating Amifampridine Phosphate and Placebo Oral Tablet for Lambert-Eaton Myasthenic Syndrome. Completed, enrolled 26 participants across 1 site.
Detailed Summary
This study evaluates the effect of withdrawing amifampridine phosphate treatment from patients with LEMS. One half of the patients will continue to receive amifampridine phosphate and the other half will receive placebo, during this double-blind study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLambert-Eaton Myasthenic Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedNov 2016
Primary CompletionOct 2017
TodayJul 2026
First PostedNov 21, 2016
Enrollment StartNov 1, 2016
Primary CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.6 years ago
Interventions
Amifampridine Phosphatedrug
Placebo Oral Tabletdrug